TW202045134A - Use of seed coat extracts of fagopyrum tataricum for slowing skin aging and manufacturing method thereof - Google Patents
Use of seed coat extracts of fagopyrum tataricum for slowing skin aging and manufacturing method thereof Download PDFInfo
- Publication number
- TW202045134A TW202045134A TW109119752A TW109119752A TW202045134A TW 202045134 A TW202045134 A TW 202045134A TW 109119752 A TW109119752 A TW 109119752A TW 109119752 A TW109119752 A TW 109119752A TW 202045134 A TW202045134 A TW 202045134A
- Authority
- TW
- Taiwan
- Prior art keywords
- seed coat
- tartary buckwheat
- buckwheat seed
- extract
- composition
- Prior art date
Links
- 244000130270 Fagopyrum tataricum Species 0.000 title claims abstract description 89
- 235000014693 Fagopyrum tataricum Nutrition 0.000 title claims abstract description 89
- 239000000284 extract Substances 0.000 title claims abstract description 77
- 238000004519 manufacturing process Methods 0.000 title description 9
- 230000009759 skin aging Effects 0.000 title description 6
- 102000008186 Collagen Human genes 0.000 claims abstract description 43
- 108010035532 Collagen Proteins 0.000 claims abstract description 43
- 229920001436 collagen Polymers 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 102000016942 Elastin Human genes 0.000 claims abstract description 26
- 108010014258 Elastin Proteins 0.000 claims abstract description 26
- 229920002549 elastin Polymers 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 102000016362 Catenins Human genes 0.000 claims description 12
- 108010067316 Catenins Proteins 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 40
- 230000036252 glycation Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 240000008620 Fagopyrum esculentum Species 0.000 description 12
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 241000212749 Zesius chrysomallus Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000001815 facial effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000036548 skin texture Effects 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 229930091371 Fructose Natural products 0.000 description 5
- 239000005715 Fructose Substances 0.000 description 5
- 239000012490 blank solution Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- -1 patch (patch) Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000004162 soil erosion Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本發明係關於一種植物萃取物的用途，特別是關於一種苦蕎麥種皮萃取物用於製備減緩皮膚老化之組合物的用途以及其製備方法。The present invention relates to the use of a plant extract, in particular to the use of a tartary buckwheat seed coat extract to prepare a composition for slowing skin aging and a preparation method thereof.
皮膚對於人類個體提供對抗陽光中紫外線（ultraviolet，UV）輻射、病原體、摩擦力等環境因子的第一階段保護。皮膚由外向內依序包含表皮層、主要由結締組織所構成的真皮層、及皮下組織。其中，真皮層包含有膠原蛋白（collagen）、彈力蛋白（elastin）、及玻尿酸（hyaluronic acid）等分子，而膠原蛋白有如肌膚中的「支架」，彈力蛋白則有如肌膚中的「拴鎖」，藉由彈力蛋白將膠原蛋白進行連結，可賦予肌膚支撐性以及彈性。The skin provides human individuals with the first stage of protection against environmental factors such as ultraviolet (UV) radiation, pathogens and friction in the sun. The skin includes the epidermis layer, the dermis layer mainly composed of connective tissue, and the subcutaneous tissue from the outside to the inside. Among them, the dermis contains molecules such as collagen, elastin, and hyaluronic acid. Collagen is like the "scaffold" in the skin, and elastin is like the "tether" in the skin. The collagen is linked by elastin to give support and elasticity to the skin.
膠原蛋白是肌膚中重要的基質蛋白，是具有三重螺旋的長鏈結構，在真皮層佔有較高的重量比例，為皮膚提供結構穩定性。而根據近期研究，膠原蛋白鏈的斷裂的其中一個可能因素是膠原蛋白的醣化（Non-enzymatic glycation，於蛋白質分子上附加糖類分子）。由於蛋白質的醣化會導致蛋白質功能的缺失，使得膠原蛋白鏈斷裂而加速其流失速率，進而促使肌膚老化或甚至其他相關疾病的產生。Collagen is an important matrix protein in the skin. It is a long-chain structure with a triple helix. It occupies a high weight ratio in the dermis and provides structural stability to the skin. According to recent studies, one of the possible factors for the breakage of collagen chains is the non-enzymatic glycation (addition of carbohydrate molecules to protein molecules). As the glycation of protein will lead to the loss of protein function, the collagen chain will be broken and its loss rate will be accelerated, which will promote skin aging or even other related diseases.
除了過去研究較著重的膠原蛋白外，彈力蛋白亦對肌膚的整體狀態具有重要影響。彈力蛋白是一種維持結締組織彈性的蛋白質，使體內許多組織在拉伸或收縮後，能恢復它們的形狀。而隨著年齡以及所接受到的外界傷害日益增加，彈力蛋白於肌膚中的含量亦將逐漸減少。當彈力蛋白流失時，即便膠原蛋白仍有一定比例，肌膚將同樣會因失去彈性而造成鬆弛以及皺紋。In addition to collagen, which has been studied in the past, elastin also has an important effect on the overall condition of the skin. Elastin is a protein that maintains the elasticity of connective tissue, allowing many tissues in the body to restore their shape after being stretched or contracted. With age and increasing external damage received, the content of elastin in the skin will gradually decrease. When elastin is lost, even if there is still a certain proportion of collagen, the skin will also lose its elasticity and cause sagging and wrinkles.
此外，當彈力蛋白及/或膠原蛋白流失時，將間接導致皮膚厚度變薄，使得表皮層更貼近真皮層中的血管，而讓肌膚整體呈現泛紅狀態，而影響其外觀。此狀態的肌膚相較於健康狀態的肌膚亦更為敏感，而更容易產生發炎等其他皮膚症狀。In addition, when the elastin and/or collagen is lost, it will indirectly cause the skin thickness to become thinner, making the epidermis closer to the blood vessels in the dermis, and making the skin appear reddish overall, which affects its appearance. Skin in this state is also more sensitive than healthy skin, and is more prone to other skin symptoms such as inflammation.
有鑑於此，研究或開發一種可降低膠原蛋白及/或彈力蛋白流失，以減緩皮膚老化的組合物，來維持或改善肌膚外觀是有其需求的。In view of this, there is a need to research or develop a composition that can reduce the loss of collagen and/or elastin to slow down skin aging to maintain or improve the appearance of the skin.
據此，本案的一目的在於提供一種苦蕎麥種皮萃取物用於製備抑制膠原蛋白醣化的組合物之用途，其中苦蕎麥種皮萃取物係以水萃取苦蕎麥種皮而獲得。Accordingly, one purpose of this case is to provide a use of a tartary buckwheat seed coat extract for preparing a composition for inhibiting saccharification of collagen, wherein the tartary buckwheat seed coat extract is obtained by extracting the tartary buckwheat seed coat with water.
本案的另一目的在於提供一種苦蕎麥種皮萃取物用於製備降低體內彈力蛋白流失的組合物之用途，其中苦蕎麥種皮萃取物係以水萃取苦蕎麥種皮而獲得。Another purpose of this case is to provide a use of the tartary buckwheat seed coat extract for preparing a composition for reducing the loss of elastin in the body, wherein the tartary buckwheat seed coat extract is obtained by extracting the tartary buckwheat seed coat with water.
根據本案的一些實施例，組合物係用以降低血液中鎖鏈素濃度。According to some embodiments of this case, the composition is used to reduce the concentration of catenin in the blood.
根據本案的一些實施例，組合物係每日施予一所需個體並持續至少2周，其中組合物含有5克至10克的苦蕎麥種皮萃取物。According to some embodiments of this case, the composition is administered to a desired individual daily for at least 2 weeks, wherein the composition contains 5 to 10 grams of tartary buckwheat seed coat extract.
根據本案的一些實施例，組合物係進一步製備成醫藥組合物、食品組合物、或保健食品組合物。According to some embodiments of the present case, the composition is further prepared into a pharmaceutical composition, a food composition, or a health food composition.
本案的另一目的在於提供一種苦蕎麥種皮萃取物的製備方法，包括粉碎並過篩苦蕎麥種皮以形成苦蕎麥種皮粉；以及以水萃取苦蕎麥種皮粉以形成苦蕎麥種皮萃取物，其中苦蕎麥種皮粉及水的固液重量比為10：1至12：1。Another purpose of this case is to provide a preparation method of tartary buckwheat seed coat extract, which includes crushing and sieving tartary buckwheat seed coat to form tartary buckwheat seed coat powder; The solid-liquid weight ratio of buckwheat seed coat powder and water is 10:1 to 12:1.
根據本案的一些實施例，其中以水萃取苦蕎麥種皮粉以形成苦蕎麥種皮萃取物的步驟包括以水在80℃-90℃下萃取苦蕎麥種皮粉0.5-3.0小時以形成第一萃取液；冷卻第一萃取液至室溫；離心冷卻後的第一萃取液，並取其上清液為第一萃取上清液；過濾第一萃取上清液：以及減壓濃縮過濾後的第一萃取上清液以形成苦蕎麥種皮萃取物。According to some embodiments of the present case, the step of extracting tartary buckwheat seed coat powder with water to form a tartary buckwheat seed coat extract includes extracting tartary buckwheat seed coat powder with water at 80°C-90°C for 0.5-3.0 hours to form the first extract; Cool the first extract to room temperature; centrifuge the cooled first extract, and take the supernatant as the first extraction supernatant; filter the first extraction supernatant: and concentrate the filtered first extraction under reduced pressure The supernatant is used to form a tartary buckwheat seed coat extract.
在一些實施例中，減壓濃縮的溫度範圍值為45-70℃。In some embodiments, the temperature range of concentration under reduced pressure is 45-70°C.
以下將描述本案的部分具體實施態樣。在不背離本案精神下，本案尚可以多種不同形式之態樣來實踐，不應將保護範圍限於說明書所具體陳述的條件。The following will describe some specific implementation aspects of this case. Without departing from the spirit of this case, this case can still be practiced in many different forms, and the scope of protection should not be limited to the conditions specified in the specification.
本案使用Excel軟體進行統計分析。數據以平均值±標準差（SD）表示，各組之間的差異以學生t 檢驗（student'st -test）進行分析。This case uses Excel software for statistical analysis. Data mean ± standard deviation (SD), said difference between the groups in a Student's t-test (student's t -test) was analyzed.
蕎麥屬（Fagopyrum ）中常見並可供食用的，可例舉如普通蕎麥（Fagopyrum esculentum ，又可稱蕎麥）以及苦蕎麥（Fagopyrum tataricum ，又可稱韃靼蕎麥）等物種。普通蕎麥普遍地生長於各大洲，而源自於西藏東部或雲南西北部的苦蕎麥則僅於亞洲、歐洲與北美洲種植。相較於稻，蕎麥屬生長期較短，可以在貧瘠的酸性土壤中生長，不需要過多的養分和氮素，但需要有充足的水分，可在比較涼爽的氣候下開花。故除了作為糧食外，可以在受水災以後作為補種，也可以作為綠肥、飼料或防止水土流失的覆蓋植物。Fagopyrum ( Fagopyrum ) is common and edible, such as common buckwheat ( Fagopyrum esculentum , also called buckwheat) and tartary buckwheat ( Fagopyrum tataricum , also called buckwheat) and other species. Ordinary buckwheat is commonly grown on all continents, while tartary buckwheat originating in eastern Tibet or northwestern Yunnan is only grown in Asia, Europe and North America. Compared with rice, buckwheat has a shorter growth period and can grow in barren acid soil. It does not require too much nutrients and nitrogen, but it needs sufficient water to bloom in a cooler climate. Therefore, in addition to being used as food, it can be used as replanting after floods, or as green manure, fodder or covering plants to prevent soil erosion.
一般而言，植物的種子一般由種皮、胚和胚乳三個部分組成，蕎麥屬的種子亦相同。本案發現蕎麥屬當中的苦蕎麥，其種皮的萃取物具有減少體內彈性蛋白、膠原蛋白流失速度的功效，而可用於製備降低體內彈性蛋白、膠原蛋白流失的組合物的用途。而由於苦蕎麥種皮萃取物具有前述的功效，故可用以改善肌膚皺紋、肌膚泛紅等因彈性蛋白、膠原蛋白流失所產生的皮膚問題，進而改善整體肌膚外觀。Generally speaking, the seeds of plants are generally composed of three parts: seed coat, embryo and endosperm. The seeds of Fagopyrum are the same. In this case, it was discovered that the extract of the seed coat of tartary buckwheat in the genus Buckwheat has the effect of reducing the loss of elastin and collagen in the body, and can be used to prepare a composition for reducing the loss of elastin and collagen in the body. And because the tartary buckwheat seed coat extract has the aforementioned effects, it can be used to improve skin wrinkles, skin redness and other skin problems caused by the loss of elastin and collagen, thereby improving the overall skin appearance.
本文中所使用的用語「苦蕎麥種皮萃取物」，為苦蕎麥種皮與溶劑（例如水）經一特定時間與溫度萃取而得。The term "tartary buckwheat seed coat extract" used in this article is obtained by extracting tartary buckwheat seed coat and solvent (such as water) after a specific time and temperature.
本案的苦蕎麥種皮萃取物可用於製備降低體內彈性蛋白流失的組合物或是抑制膠原蛋白醣化的組合物，而組合物可為醫藥組合物、食品組合物、保健食品組合物。或者，食品或保養品中可包含有本案的醫藥組合物。或本案的苦蕎麥種皮萃取物可進一步製備成醫藥組合物、保養品組合物、食品組合物、或保健食品組合物。The tartary buckwheat seed coat extract in this case can be used to prepare a composition that reduces the loss of elastin in the body or a composition that inhibits the saccharification of collagen, and the composition can be a pharmaceutical composition, a food composition, or a health food composition. Alternatively, the food or skin care product may contain the pharmaceutical composition of this case. Or the tartary buckwheat seed coat extract of this case can be further prepared into a pharmaceutical composition, a skin care product composition, a food composition, or a health food composition.
醫藥組合物可利用熟習此技藝者所詳知的技術而被製造成一適合於非經腸道地（parenterally）或局部地（topically）投藥的劑型，這包括，但不限於：注射品（injection）[例如，無菌的水性溶液（sterile aqueous solution）或分散液（dispersion）]、無菌的粉末（sterile powder）、外部製劑（external preparation）以及類似物。The pharmaceutical composition can be manufactured into a dosage form suitable for parenterally or topically by using techniques well-known to those skilled in the art. This includes, but is not limited to: injection [For example, a sterile aqueous solution or dispersion], a sterile powder, an external preparation, and the like.
醫藥組合物可進一步包含有一被廣泛地使用於藥物製造技術之醫藥上可接受的載劑（pharmaceutically acceptable carrier）。例如，該醫藥上可接受的載劑可包含一或多種選自於下列的試劑：溶劑（solvent）、緩衝液（buffer）、乳化劑（emulsifier）、懸浮劑（suspending agent）、分解劑（decomposer）、崩解劑（disintegrating agent）、分散劑（dispersing agent）、黏結劑（binding agent）、賦形劑（excipient）、安定劑（stabilizing agent）、螯合劑（chelating agent）、稀釋劑（diluent）、膠凝劑（gelling agent）、防腐劑（preservative）、潤濕劑（wetting agent）、潤滑劑（lubricant）、吸收延遲劑（absorption delaying agent）、脂質體（liposome）以及類似之物。有關這些試劑的選用與數量是熟習此項技術人員可視情況進行選擇的。The pharmaceutical composition may further include a pharmaceutically acceptable carrier that is widely used in pharmaceutical manufacturing technology. For example, the pharmaceutically acceptable carrier may include one or more reagents selected from the group consisting of solvents, buffers, emulsifiers, suspending agents, decomposers ), disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent , Gelling agent, preservative, wetting agent, lubricant, absorption delaying agent, liposome and the like. The selection and quantity of these reagents can be selected by those skilled in the art according to the situation.
在一些實施例中，該醫藥上可接受的載劑包含有一選自於由下列所構成之群組中的溶劑：水、生理鹽水（normal saline）、磷酸鹽緩衝生理鹽水（phosphate buffered saline，PBS）、含有醇的水性溶液（aqueous solution containing alcohol）以及它們的組合。In some embodiments, the pharmaceutically acceptable carrier includes a solvent selected from the group consisting of water, normal saline, and phosphate buffered saline (PBS). ), aqueous solution containing alcohol (aqueous solution containing alcohol) and their combinations.
在一些實施例中，該醫藥組合物可以一選自於由下列所構成之群組中的非經腸道途徑（parenteral routes）來投藥：皮下注射（subcutaneous injection）、表皮內注射（intraepidermal injection）、皮內注射（intradermal injection）以及病灶內注射（intralesional injection）。In some embodiments, the pharmaceutical composition may be administered by parenteral routes selected from the group consisting of: subcutaneous injection, intraepidermal injection , Intradermal injection and intralesional injection.
在一些實施例中，醫藥組合物可利用熟習此技藝者所詳知的技術而被製造成一適合於局部地施用於皮膚上的外部製劑（external preparation），這包括，但不限於：乳劑（emulsion）、凝膠（gel）、軟膏（ointment）、乳霜（cream）、貼片（patch）、擦劑（liniment）、粉末（powder）、氣溶膠（aerosol）、噴霧（spray）、乳液（lotion）、乳漿（serum）、糊劑（paste）、泡沫（foam）、滴劑（drop）、懸浮液（suspension）、油膏（salve）以及繃帶（bandage）。In some embodiments, the pharmaceutical composition can be manufactured into an external preparation suitable for topical application to the skin using techniques well known to those skilled in the art. This includes, but is not limited to: emulsion ), gel (gel), ointment (cream), patch (patch), liniment, powder (powder), aerosol (aerosol), spray (spray), lotion (lotion) ), serum, paste, foam, drop, suspension, salve and bandage.
在一些實施例中，外部製劑是藉由將醫藥組合物與一為熟習此項技藝者所詳知的基底（base）相混合而製成。In some embodiments, the external preparation is made by mixing the pharmaceutical composition with a base well known to those skilled in the art.
在一些實施例中，該基底可包含有一或多種選自於下列的添加劑（additives）：水、醇（alcohols）、甘醇（glycol）、碳氫化合物（hydrocarbons）[諸如石油膠（petroleum, jelly）以及白凡士林（white petrolatum,）]、蠟（wax）[諸如石蠟（paraffin）以及黃蠟（yellow wax）]、保存劑（preserving agents）、抗氧化劑（antioxidants）、界面活性劑（surfactants）、吸收增強劑（absorption enhancers）、安定劑（stabilizing agents）、膠凝劑（gelling agents）[諸如卡波普®974P （carbopol®974P）、微結晶纖維素（microcrystalline cellulose）以及羧基甲基纖維素（carboxymethylcellulose）]、活性劑（active agents）、保濕劑（humectants）、氣味吸收劑（odor absorbers）、香料（fragrances）、pH調整劑（pH adjusting agents）、螯合劑（chelating agents）、乳化劑（emulsifiers）、閉塞劑（occlusive agents）、軟化劑（emollients）、增稠劑（thickeners）、助溶劑（solubilizing agents）、滲透增強劑（penetration enhancers）、抗刺激劑（anti-irritants）、著色劑（colorants）以及推進劑（propellants）等。有關這些添加劑的選用與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。In some embodiments, the substrate may include one or more additives selected from the following: water, alcohols, glycols, hydrocarbons (such as petroleum jelly (petroleum, jelly) ) And white petrolatum (white petrolatum,)], wax (such as paraffin and yellow wax), preserving agents, antioxidants, surfactants, absorption Enhancers (absorption enhancers), stabilizers (stabilizing agents), gelling agents (such as Carbopol®974P (carbopol®974P), microcrystalline cellulose) and carboxymethylcellulose (carboxymethylcellulose) )], active agents, humectants, odor absorbers, fragrances, pH adjusting agents, chelating agents, emulsifiers , Occlusive agents, emollients, thickeners, solubilizing agents, penetration enhancers, anti-irritants, colorants And propellants, etc. The selection and quantity of these additives fall within the scope of professionalism and routine technology of those who are familiar with this technology.
在一些實施例中，保養品中可包含有一被廣泛地使用於保養品製造技術之可接受的佐劑（acceptable adjuvant）。例如，該可接受的佐劑可包含有一或多種選自於下列的試劑：溶劑、膠凝劑、活性劑、防腐劑、抗氧化劑、遮蔽劑（screening agent）、螯合劑、界面活性劑、染色試劑（coloring agent）、增稠劑（thickening agent）、填料（filler）、香料以及氣味吸收劑。可根據實際需求對這些試劑的選用與數量進行合適的調整。In some embodiments, the skin care product may include an acceptable adjuvant that is widely used in skin care product manufacturing technology. For example, the acceptable adjuvant may contain one or more agents selected from the group consisting of solvents, gelling agents, active agents, preservatives, antioxidants, screening agents, chelating agents, surfactants, dyes Coloring agent, thickening agent, filler, fragrance and odor absorber. The selection and quantity of these reagents can be appropriately adjusted according to actual needs.
在一些實施例中，保養品可利用熟習此技藝者所詳知的技術而被製造成一適合於護膚（skincare）或化妝（makeup）的形式，包括，但不限於：水性溶液（aqueous solution）、水-醇溶液（aqueous-alcohol solution）或油性溶液（oily solution）、呈水包油型（oil-in-water type）、油包水型（water-in-oil type）或複合型之乳劑、凝膠、軟膏、乳霜、面膜（mask）、貼片、貼布（pack）、擦劑、粉末、氣溶膠、噴霧、乳液、乳漿、糊劑、泡沫、分散液、滴劑、慕斯（mousse）、防曬油（sunblock）、化妝水（tonic water）、粉底（foundation）、卸妝產品（makeup remover products）、肥皂（soap）以及其他身體清潔產品（body cleansing products）等。In some embodiments, the skin care product can be manufactured into a form suitable for skincare or makeup using techniques well known to those skilled in the art, including, but not limited to: aqueous solution, Water-alcohol solution (aqueous-alcohol solution) or oily solution (oily solution), oil-in-water type, water-in-oil type or composite emulsion, Gel, ointment, cream, mask, patch, pack, liniment, powder, aerosol, spray, lotion, cream, paste, foam, dispersion, drops, mousse (Mousse), sunblock (sunblock), tonic water, foundation (foundation), makeup remover products, soap and other body cleansing products, etc.
在一些實施例中，保養品亦可與一或多種選自於下列之已知活性的外用劑（external use agents）一起合併使用：美白劑（whitening agents）[諸如維生素A酸（tretinoin）、兒茶素（catechin）、麴酸、熊果苷以及維生素C]、保濕劑、殺菌劑（bactericides）、紫外線吸收劑（ultraviolet absorbers）、植物萃取物（plant extracts）[諸如蘆薈萃取物（aloe extract）]、皮膚營養劑（skin nutrients）、麻醉劑（anesthetics）、抗痘劑（anti-acne agents）、止癢劑（antipruritics）、止痛劑（analgesics）、抗皮膚炎劑（antidermatitis agents）、抗過角化劑（antihyperkeratolytic agents）、抗乾皮膚劑（anti-dry skin agents）、抗汗劑（antipsoriatic agents）、抗老化劑（antiaging agents）、抗皺劑（antiwrinkle agents）、抗皮脂溢出劑（antiseborrheic agents）、傷口治療劑（wound-healing agents）、皮質類固醇（corticosteroids）以及激素（hormones）。有關這些外用劑的選用與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。In some embodiments, the skin care product can also be used in combination with one or more external use agents with known activity selected from the following: whitening agents (such as tretinoin, tretinoin) Catechin, koji acid, arbutin and vitamin C], humectants, bactericides, ultraviolet absorbers, plant extracts (such as aloe extract) ], skin nutrients, anesthetics, anti-acne agents, antipruritics, analgesics, antidermatitis agents, anti-acne Antihyperkeratolytic agents, anti-dry skin agents, antipsoriatic agents, antiaging agents, antiwrinkle agents, antiseborrheic agents , Wound-healing agents, corticosteroids and hormones. The selection and quantity of these topical agents fall within the scope of professionalism and routine techniques of those who are familiar with this technology.
在一些實施例中，醫藥組合物可被當作食品添加物（food additive），藉由習知方法於原料製備時添加，或是於食品的製作過程中添加，而與任一種可食性材料配製成供人類與非人類動物攝食的食品產品。In some embodiments, the pharmaceutical composition can be used as a food additive, which is added during the preparation of raw materials by a conventional method, or added during the preparation of food, and is formulated with any edible material. Produce food products for human and non-human animals to eat.
在一些實施例中，食品的種類包括但不限於：飲料（beverages）、發酵食品（fermented foods）、烘培產品（bakery products）、健康食品（health foods）以及膳食補充品（dietary supplements）。In some embodiments, the types of food include, but are not limited to: beverages, fermented foods, bakery products, health foods, and dietary supplements.
以下將詳細說明苦蕎麥種皮萃取物的萃取方法以及與蕎麥種皮萃取物相關的檢測方法。The following details the extraction method of tartary buckwheat seed coat extract and the detection method related to buckwheat seed coat extract.
[[ 例example 1]1] 苦蕎麥種皮萃取物的製備方法Preparation method of tartary buckwheat seed coat extract
在此實施例中，苦蕎麥種皮萃取物的製備步驟如下： 1. 將苦蕎麥（產地：台灣）的種皮經粉碎並以10目數（mesh）的篩網將其過篩，去除過大顆粒後取得苦蕎麥種皮粉。在另一些實施例中，篩網的目數可為8目或12目。 2. 將水與苦蕎麥種皮粉以11：1的重量比混合，並於85±5℃下浸泡約1.0小時以萃取苦蕎麥種皮粉，形成含有固體的第一萃取液。在另一些實施例中，溶劑與苦蕎麥種皮粉的重量比亦可為10：1至12：1，浸泡時的溫度可為80℃-90℃，萃取時間可為0.5至3.0小時。若溶劑過少或萃取時間過短，則萃取效率將會明顯下降；若萃取時間過長，則萃取物中的有效成分可能會產生降解。 3. 冷卻第一萃取液至室溫（25℃-30℃）。 4. 將冷卻後帶有固體的第一萃取液經離心機（廠牌/型號：Thermo Scientific Heraeus Fresco 17）離心約10分鐘，取其上清液為第一萃取上清液。 5. 將第一萃取上清液以400目數的濾網進行過濾，去除細微固體。 6. 將過濾後的第一萃取上清液以濃縮機（廠牌/型號：BUCHI -Rotavapor R-100），在60℃±5℃下進行減壓濃縮至溶液的白利糖度值（Degrees Brix）為2.0±0.5時停止濃縮，得到苦蕎麥種皮萃取物。在另一些實施例中，可於45℃-70℃下進行減壓濃縮。In this embodiment, the preparation steps of the tartary buckwheat seed coat extract are as follows: 1. The seed coat of tartary buckwheat (origin: Taiwan) is crushed and sieved with a 10 mesh screen to remove large particles to obtain the seed coat powder of tartary buckwheat. In other embodiments, the mesh number of the screen may be 8 mesh or 12 mesh. 2. Mix water and tartary buckwheat seed coat powder in a weight ratio of 11:1, and soak at 85±5°C for about 1.0 hour to extract the tartary buckwheat seed coat powder to form the first extract containing solids. In other embodiments, the weight ratio of the solvent to the tartary buckwheat seed coat powder can also be 10:1 to 12:1, the temperature during soaking can be 80°C-90°C, and the extraction time can be 0.5 to 3.0 hours. If the solvent is too little or the extraction time is too short, the extraction efficiency will be significantly reduced; if the extraction time is too long, the active ingredients in the extract may be degraded. 3. Cool the first extract to room temperature (25℃-30℃). 4. Centrifuge the cooled first extract with solids in a centrifuge (brand/model: Thermo Scientific Heraeus Fresco 17) for about 10 minutes, and take the supernatant as the first extraction supernatant. 5. Filter the first extraction supernatant with a 400 mesh filter to remove fine solids. 6. Use a concentrator (brand/model: BUCHI-Rotavapor R-100) to concentrate the filtered first extraction supernatant under reduced pressure at 60℃±5℃ to reach the Brix value of the solution (Degrees Brix). ) When it is 2.0±0.5, stop the concentration and obtain the tartary buckwheat seed coat extract. In other embodiments, concentration under reduced pressure may be performed at 45°C to 70°C.
[[ 例example 2]2] 膠原蛋白醣化量檢測Detection of collagen glycation amount
如同先前所述，膠原蛋白鏈的斷裂的其中一個因素是膠原蛋白的醣化。當蛋白質經醣化反應後將生成多種醣化終產物（Advanced glycation end products，AGEs），其為不可還原之物質，並改變及影響蛋白質的正常功能。因此，若能抑止膠原蛋白醣化則可防止膠原蛋白鏈斷裂，則可有效地降低膠原蛋白的流失速度。而為確認苦蕎麥種皮萃取物是否具有抑止膠原蛋白醣化的功效，進行膠原蛋白醣化量測試如下。As mentioned earlier, one of the factors for the breakage of collagen chains is the glycation of collagen. When a protein undergoes a glycation reaction, a variety of advanced glycation end products (AGEs) will be produced, which are non-reducible substances and change and affect the normal function of the protein. Therefore, if the glycation of collagen can be inhibited, the breakage of the collagen chain can be prevented, and the rate of loss of collagen can be effectively reduced. In order to confirm whether the tartary buckwheat seed coat extract has the effect of inhibiting the glycation of collagen, the amount of glycation of collagen was tested as follows.
藥品配製： 1. 使用前方例1中所製得苦蕎麥種皮萃取物，以濃度200 mM的磷酸鹽緩衝生理鹽水（Phosphate-Buffered Saline，PBS，係以NaH2 PO3 （Honeywell，#04269）、Na2 HPO4 （Sigma，#V900061）與水配製而成，其pH值為7.4）作為溶劑，分別配製出濃度0.1 mg/mL、0.5 mg/mL、1.0 mg/mL、以及5 mg/mL的苦蕎麥種皮萃取物溶液。 2. 使用前述濃度200 mM的磷酸鹽緩衝生理鹽水以及膠原蛋白粉末（膠原蛋白購自Rousselot，型號#P2000HD），配製濃度為60 mg/mL的膠原蛋白溶液。另加入疊氮化鈉於膠原蛋白溶液中，使膠原蛋白溶液中含有0.06wt％的疊氮化鈉。（疊氮化鈉購自Sigma，#S2002） 3. 使用前述濃度200 mM的磷酸鹽緩衝生理鹽水與果糖（果糖購自Sigma，#F0127），配製濃度為1.5M的果糖溶液。Pharmaceutical preparation: 1. Use the tartary buckwheat seed coat extract prepared in Example 1 above, with a concentration of 200 mM Phosphate-Buffered Saline (Phosphate-Buffered Saline, PBS, NaH 2 PO 3 (Honeywell, #04269), Na 2 HPO 4 (Sigma, #V900061) is prepared with water with a pH of 7.4) as the solvent, and the concentrations of 0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, and 5 mg/mL Tartary buckwheat seed coat extract solution. 2. Use the aforementioned 200 mM phosphate buffered saline and collagen powder (collagen purchased from Rousselot, model #P2000HD) to prepare a collagen solution with a concentration of 60 mg/mL. In addition, sodium azide is added to the collagen solution so that the collagen solution contains 0.06 wt% sodium azide. (Sodium azide purchased from Sigma, #S2002) 3. Use the aforementioned 200 mM phosphate buffered saline and fructose (fructose purchased from Sigma, #F0127) to prepare a fructose solution with a concentration of 1.5M.
膠原蛋白醣化測試： 1. 將前述4種濃度的苦蕎麥種皮萃取物溶液0.2 mL，分別與0.2 mL前述膠原蛋白溶液以及0.2 mL前述果糖溶液進行混合，配製出4組樣品溶液。 2. 將0.2 mL的去離子水與0.2 mL前述膠原蛋白溶液以及0.2 mL前述果糖溶液進行混合，配製出空白溶液作為控制組。 3. 將4組樣品溶液以及空白溶液於進行膠原蛋白醣化反應前，使用分光螢光計（spectrofluorometer，廠商/型號：BioTek FLx 800）測量其螢光強度（激發波長360 nm，放射波長460 nm）。 4. 將4組樣品溶液以及空白溶液置於50℃反應24小時，使各溶液進行膠原蛋白醣化反應。 5. 將反應後的4組樣品溶液以及空白溶液，同樣以分光螢光計測量其螢光強度（激發波長360 nm，放射波長460 nm）。 6. 依下列公式計算蛋白質醣化終產物相對生成率： [(樣品螢光強度反應後 - 樣品螢光強度反應前 )/(控制組螢光強度反應後 - 控制組螢光強度反應前 )]×100% 各樣品相對於控制組的蛋白質醣化終產物相對生成率顯示於圖1。Collagen saccharification test: 1. Mix 0.2 mL of the aforementioned four concentrations of tartary buckwheat seed coat extract solution with 0.2 mL of the aforementioned collagen solution and 0.2 mL of the aforementioned fructose solution to prepare 4 sets of sample solutions. 2. Mix 0.2 mL of deionized water with 0.2 mL of the aforementioned collagen solution and 0.2 mL of the aforementioned fructose solution to prepare a blank solution as the control group. 3. Use a spectrofluorometer (manufacturer/model: BioTek FLx 800) to measure the fluorescence intensity (excitation wavelength 360 nm, emission wavelength 460 nm) of the 4 sets of sample solutions and blank solutions before the collagen glycation reaction. . 4. Place the 4 sets of sample solutions and blank solutions at 50°C for 24 hours to allow each solution to undergo collagen glycation reaction. 5. Measure the fluorescence intensity of the 4 groups of sample solutions and blank solutions after the reaction with a spectrofluorometer (excitation wavelength 360 nm, emission wavelength 460 nm). 6. Calculate the relative production rate of the final protein glycation product according to the following formula: [( After the fluorescence intensity reaction of the sample- before the fluorescence intensity reaction of the sample)/( After the fluorescence intensity reaction of the control group- Before the fluorescence intensity reaction of the control group)]× The relative production rate of the final protein glycation products of each sample relative to the control group is shown in Figure 1.
如圖1所示，各濃度（0.1 mg/mL、0.5 mg/mL、1.0 mg/mL、以及5 mg/mL）的苦蕎麥種皮萃取物皆具有抑止膠原蛋白的醣化終產物產生的效果，且與苦蕎麥種皮萃取物的濃度具有相關性。於0.1 mg/mL、0.5 mg/mL、1.0 mg/mL、以及5 mg/mL的苦蕎麥種皮萃取物樣品溶液中，蛋白質醣化終產物相對生成率分別僅為控制組的92％、48％、31％、19％。顯示苦蕎麥種皮萃取物確實可抑止膠原蛋白的醣化反應，減少醣化終產物的生成，進而降低體內膠原蛋白的流失，達到減緩肌膚老化的功效。As shown in Figure 1, each concentration (0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, and 5 mg/mL) of tartary buckwheat seed coat extract has the effect of inhibiting the production of the end product of collagen glycation, and It is correlated with the concentration of tartary buckwheat seed coat extract. In 0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, and 5 mg/mL tartary buckwheat seed coat extract sample solutions, the relative production rates of protein glycation end products were only 92%, 48%, 31%, 19%. It shows that the extract of tartary buckwheat seed coat can indeed inhibit the glycation reaction of collagen, reduce the production of glycation end products, thereby reducing the loss of collagen in the body, and achieve the effect of slowing down skin aging.
[[ 例example 3]3] 體內鎖鏈素含量檢測In vivo catenin content detection
彈力蛋白中具有一種特殊的成分—鎖鏈素（Desmosine），其是由三個醛賴氨酸側鏈和一個賴氨酸側鏈所形成的交聯體，可使膠原蛋白分子中2條以上的多肽鏈之間發生共價交聯。鎖鏈素特殊的構造與性質賦予彈力蛋白彈性以及連結性，使彈力蛋白可作為肌膚中膠原蛋白之間的「拴鎖」。Elastin has a special component-Desmosine, which is a cross-linked body formed by three aldehyde-lysine side chains and one lysine side chain, which can make more than two collagen molecules Covalent cross-linking occurs between the polypeptide chains. The special structure and properties of catenin give elastin elasticity and connectivity, so that elastin can act as a "tether" between collagen in the skin.
當彈力蛋白被分解時，其中所含的鎖鏈素即被釋放至血液中，使得血液中的鎖鏈素濃度升高；反之，若彈力蛋白的分解量減少，則血液中的鎖鏈素濃度將下降。因此，血液中鎖鏈素的濃度可作為彈性蛋白分解量的指標。而為確認苦蕎麥種皮萃取物是否可抑止彈力蛋白分解，進行體內鎖鏈素含量檢測如下。When elastin is decomposed, the catenin contained in it is released into the blood, causing the concentration of catenin in the blood to increase; conversely, if the decomposition amount of elastin decreases, the concentration of catenin in the blood will decrease. Therefore, the concentration of catenin in the blood can be used as an indicator of the amount of elastin decomposition. In order to confirm whether tartary buckwheat seed coat extract can inhibit the decomposition of elastin, the content of catenin in the body was tested as follows.
將例1中所製得的苦蕎麥種皮萃取物與水配製成苦蕎麥種皮萃取物飲品。並請8位受試者（30-55歲的一般女性）以每日攝取5g苦蕎麥種皮萃取物的攝取劑量飲用所配製的苦蕎麥種皮萃取物飲品，共持續4週。並於實驗開始前（第0週，尚未飲用）、第2週以及第4週對受試者進行採血，並利用Desmosine ELISA Kit（CUSABIO, CSB-E12871h）對血液中的鎖鏈素濃度進行測量（以下步驟所使用的藥品，除非特別敘明，皆由Desmosine ELISA Kit所提供）。The tartary buckwheat seed coat extract prepared in Example 1 and water were prepared into a tartary buckwheat seed coat extract drink. In addition, 8 subjects (general women aged 30-55) were invited to drink the prepared tartary buckwheat seed coat extract drink at a daily intake of 5 g of tartary buckwheat seed coat extract for a total of 4 weeks. And before the start of the experiment (week 0, not drinking), the second week and the fourth week, the subjects were collected blood, and the Desmosine ELISA Kit (CUSABIO, CSB-E12871h) was used to measure the concentration of catenin in the blood ( The drugs used in the following steps, unless otherwise specified, are provided by Desmosine ELISA Kit).
血液中鎖鏈素濃度的測量方式： 1. 從採集到的全血樣本中分離出血清樣本。 2. 將每個血清樣本、一組依序列稀釋具有已知濃度的鎖鏈素標準品（用以製作檢量線）、以及空白溶液，以微量吸管吸取100 μl至Desmosine ELISA Kit專用的96孔盤中。 3. 將前述96孔盤放置於37℃烘箱中反應2小時。 4. 去除96孔盤中的液體。 5. 以微量吸管吸取100 μl的Biotin-antibody（1x）至96孔盤中的每個孔中。 6. 再將96孔盤放置回37℃烘箱中反應1小時。 7. 去除96孔盤中的液體。 8. 以Wash buffer（濃度200 mM的磷酸鹽緩衝生理鹽水，pH值為7.4）清洗96孔盤3次，每次的步驟如下： (1) 每個孔加入200 μl的Wash buffer。 (2) 靜置2分鐘。 (3) 去除96孔盤中的液體。 9. 以微量吸管吸取100 μl的HRP-avidin（1x）至96孔盤中的每個孔中。 10. 將96孔盤放置回37℃烘箱中反應1小時。 11. 以Wash buffer清洗96孔盤3次，即重複步驟8.三次。 12. 以微量吸管吸取90 μl的TMB（3,3’,5,5’-Tetramethylbenzidine） Substrate至96孔盤中的每個孔中。 13. 將96孔盤放置回37℃烘箱中反應15分鐘。 14. 以微量吸管吸取50 μl的Stop Solution至96孔盤中的每個孔中。 15. 用ELISA reader（BioTek，FLx 800）對波長450nm和540nm的吸光值進行測定。 16. 利用Excel建立標準曲線，以540nm的吸光值對450nm的吸光值進行校正（使用波長450nm以及540nm檢測每孔的吸光值，再將波長450nm的吸光值減去波長540nm的吸光值），並進行樣本的定量換算。 17. 利用Excel中的Student-t test統計分析樣本。The method of measuring the concentration of chain chain in the blood: 1. Separate a serum sample from the collected whole blood sample. 2. Take each serum sample, a set of catenin standards diluted in sequence with known concentrations (to make a calibration line), and a blank solution, and use a micropipette to draw 100 μl into a 96-well plate dedicated to Desmosine ELISA Kit in. 3. Place the aforementioned 96-well plate in a 37°C oven to react for 2 hours. 4. Remove the liquid in the 96-well plate. 5. Use a micropipette to pipette 100 μl of Biotin-antibody (1x) into each well of the 96-well plate. 6. Place the 96-well plate back in the 37°C oven and react for 1 hour. 7. Remove the liquid from the 96-well plate. 8. Wash the 96-well plate 3 times with Wash buffer (phosphate-buffered saline with a concentration of 200 mM, pH 7.4), the steps are as follows each time: (1) Add 200 μl of Wash buffer to each well. (2) Let stand for 2 minutes. (3) Remove the liquid in the 96-well plate. 9. Use a micropipette to draw 100 μl of HRP-avidin (1x) into each well of the 96-well plate. 10. Place the 96-well plate back in the 37°C oven for 1 hour. 11. Wash the 96-well plate 3 times with Wash buffer, that is, repeat step 8. three times. 12. Use a micropipette to pipette 90 μl of TMB (3,3’,5,5’-Tetramethylbenzidine) Substrate into each well of the 96-well plate. 13. Place the 96-well plate back in the 37°C oven for 15 minutes. 14. Use a micropipette to pipette 50 μl of Stop Solution into each well of the 96-well plate. 15. Use an ELISA reader (BioTek, FLx 800) to measure the absorbance at 450nm and 540nm. 16. Use Excel to establish a standard curve, calibrate the absorbance value at 450nm with the absorbance value at 540nm (use the wavelength 450nm and 540nm to detect the absorbance value of each hole, and then subtract the absorbance value at the wavelength of 450nm from the absorbance value at the wavelength of 540nm), and Perform quantitative conversion of samples. 17. Use the Student-t test in Excel to statistically analyze the samples.
以第0週的濃度作為100％，其血液中鎖鏈素的相對濃度的檢測結果，顯示於圖2。圖中**表示相對於基準組之p>0.01；***表示相對於基準組之p>0.001。Taking the concentration at week 0 as 100%, the detection result of the relative concentration of catenin in the blood is shown in FIG. 2. ** in the figure indicates p>0.01 relative to the reference group; *** indicates p>0.001 relative to the reference group.
如圖2所示，受試者在持續飲用苦蕎麥種皮萃取物2週後，其體內的鎖鏈素含量已顯著下降，僅約為攝取前的78.1％。而當持續飲用苦蕎麥種皮萃取物4週後，體內的鎖鏈素含量可降低至約為攝取前的65.7％。顯示受試者在攝取苦蕎麥種皮萃取物後，體內彈力蛋白的破壞量大幅降低，且隨著攝取期間的增加，其降低功效可更為明顯。故證實苦蕎麥種皮萃取物可有效減緩體內彈力蛋白的流失。As shown in Figure 2, after the subjects continued to drink the tartary buckwheat seed coat extract for 2 weeks, the content of sclerotin in their body had decreased significantly, which was only about 78.1% of that before ingestion. And when the tartary buckwheat seed coat extract is consumed continuously for 4 weeks, the content of cinerein in the body can be reduced to approximately 65.7% of the level before ingestion. It was shown that after the subjects ingested the tartary buckwheat seed coat extract, the amount of destruction of elastin in the body was greatly reduced, and as the intake period increased, the reduction effect could be more obvious. Therefore, it is proved that the extract of tartary buckwheat seed coat can effectively slow down the loss of elastin in the body.
[[ 例example 4]4] 皮膚紋理改善測試Skin texture improvement test // 肌膚紅色斑點相對量檢測Detection of the relative amount of red spots on the skin
將例1中所製得的苦蕎麥種皮萃取物與水配製成苦蕎麥種皮萃取物飲品，以提供受試者合適的有效劑量。於此實施例中，請8位受試者（30-55歲的一般女性）以每日攝取5g苦蕎麥種皮萃取物的攝取劑量飲用所配製的苦蕎麥種皮萃取物飲品，共持續4週。並於實驗開始前（第0週，尚未飲用）、第2週以及第4週對受試者已清潔過的面部肌膚，以全臉膚質檢測儀（7th Generation VISIA Complexion Analysis System；Canfield，USA）測定該些受試者的全臉皮膚紋理及紅色斑點數量以及面積。The tartary buckwheat seed coat extract prepared in Example 1 and water were formulated into a tartary buckwheat seed coat extract drink to provide subjects with a suitable effective dose. In this example, 8 subjects (general women aged 30-55) were asked to drink the prepared tartary buckwheat seed coat extract drink at a daily intake of 5 g of tartary buckwheat seed coat extract for 4 weeks. And before the start of the experiment (week 0, not drunk), the second week and the fourth week of the subject’s cleansed facial skin, the whole face skin quality tester (7th Generation VISIA Complexion Analysis System; Canfield, USA) ) Determine the skin texture and the number and area of red spots on the entire face of these subjects.
關於皮膚紋理的檢測結果以及實際的外觀變化，分別顯示於圖3以及圖4至圖6。圖3係以受試者攝取苦蕎麥種皮萃取物前的皮膚粗糙度為100％，並記錄受試者攝取苦蕎麥種皮萃取物2週、4週後的相對皮膚粗糙度。圖4至圖6係其中一位受試者臉部肌膚在第0週、第2週、第4週的實拍照片，其中紋理部分經由軟體處理進行標記。The detection results of skin texture and actual appearance changes are shown in Figure 3 and Figures 4 to 6, respectively. Figure 3 takes the skin roughness of the test subject before ingesting the tartary buckwheat seed coat extract as 100%, and records the relative skin roughness of the test subject after ingesting the tartary buckwheat seed coat extract for 2 weeks and 4 weeks. Figures 4 to 6 are real photos taken of the facial skin of one of the subjects in the 0th, 2nd, and 4th weeks, in which the texture is marked by software processing.
如圖3所示，當受試者攝取苦蕎麥種皮萃取物2週後，即可開始觀察到皮膚紋理的改善，而當連續攝取4週後，皮膚紋理的相對粗糙度即下降至87.6％。由圖4至圖6的實拍照片中亦可發現，隨著攝取苦蕎麥種皮萃取物的期間增加，肌膚上的細紋明顯減少或淡化。As shown in Figure 3, when the subjects took the tartary buckwheat seed coat extract for 2 weeks, they could begin to observe the improvement of the skin texture, and after 4 weeks of continuous intake, the relative roughness of the skin texture decreased to 87.6%. It can also be found from the real shot photos in Figs. 4 to 6 that as the period of ingestion of the tartary buckwheat seed coat extract increases, the fine lines on the skin are significantly reduced or faded.
關於受試者肌膚紅色斑點數量以及面積的結果以及實際的外觀變化，分別顯示於圖7以及圖8至圖10。圖7係以受試者攝取苦蕎麥種皮萃取物前，由儀器根據紅色斑點數量以及面積所測得之數值為100％，並記錄受試者持續攝取苦蕎麥種皮萃取物2週、4週後的根據紅色斑點數量/面積所測得之數值。圖8至圖10係其中一位受試者臉部肌膚在第0週、第2週、第4週以檢測儀所拍攝的圖像。The results of the number and area of red spots on the subject’s skin and the actual appearance changes are shown in Figs. 7 and 8 to 10, respectively. Figure 7 shows that before the subject ingested the tartary buckwheat seed coat extract, the value measured by the instrument based on the number and area of the red spots was 100%, and recorded that the subjects continued to take the tartary buckwheat seed coat extract for 2 weeks and 4 weeks The value measured based on the number of red spots/area. Figures 8 to 10 are images of one of the subjects’ facial skin taken by the detector in the 0th, 2nd, and 4th weeks.
如圖7所示，當受試者攝取苦蕎麥種皮萃取物2週後，即可開始觀察到紅色斑點數量/面積的減少，而當連續攝取4週後，面部肌膚的紅色斑點數量/面積即下降至原本的95.1％。圖8至圖10的實拍影像中亦可發現，隨著攝取苦蕎麥種皮萃取物的期間增加，肌膚上的紅色斑點數量/面積明顯減少或淡化。As shown in Figure 7, when the subjects ingested tartary buckwheat seed coat extract for 2 weeks, they could begin to observe the reduction in the number/area of red spots, and after 4 weeks of continuous intake, the number/area of red spots on the facial skin was Dropped to 95.1% of the original. It can also be found in the real shot images of Figures 8 to 10 that as the period of ingestion of the tartary buckwheat seed coat extract increases, the number/area of red spots on the skin is significantly reduced or faded.
由皮膚紋理改善測試以及肌膚紅色斑點相對量檢測結果以及前述的其他實驗可知，苦蕎麥種皮萃取物可抑制膠原蛋白醣化以及降低血液中鎖鏈素濃度，進而可抑止體內膠原蛋白流失以及抑止體內彈力蛋白流失，而可用於減緩皮膚老化及/或改善肌膚外觀。From the skin texture improvement test, the relative amount of red spots on the skin and other experiments mentioned above, it can be seen that the tartary buckwheat seed coat extract can inhibit the glycation of collagen and reduce the concentration of lanolin in the blood, thereby inhibiting the loss of collagen in the body and inhibiting elastin in the body It can be used to slow down skin aging and/or improve skin appearance.
以上所述僅為舉例性，而非為限制性者。任何未脫離本發明之精神與範疇，而對其進行之等效修改或變更，均應包含於後附之申請專利範圍中。The above description is only illustrative, and not restrictive. Any equivalent modifications or alterations that do not depart from the spirit and scope of the present invention should be included in the scope of the attached patent application.
圖1顯示苦蕎麥種皮萃取物降低膠原蛋白醣化終產物的生成量。 圖2顯示苦蕎麥種皮萃取物減少受試者血液中的鎖鏈素（Desmosine）含量。**p值>0.01；***p值>0.001。 圖3顯示連續四週施用苦蕎麥種皮萃取物於受試者臉部肌膚後，其皮膚紋理的改善率。 圖4至圖6為受試者臉部肌膚分別在第0週、第2週、第4週的實拍照片（紋理部分經由軟體進行標記）。 圖7顯示連續四週施用苦蕎麥種皮萃取物於受試者臉部肌膚後，其肌膚上紅色斑點相對量的變化。*p值>0.05。 圖8至圖10為受試者臉部肌膚分別在第0週、第2週、第4週以檢測儀所拍攝的圖像。Figure 1 shows that tartary buckwheat seed coat extract reduces the production of collagen glycation end products. Figure 2 shows that tartary buckwheat seed coat extract reduces the content of Desmosine in the blood of subjects. **p value>0.01; ***p value>0.001. Figure 3 shows the improvement rate of skin texture after applying tartary buckwheat seed coat extract to the facial skin of subjects for four consecutive weeks. Figures 4 to 6 are real photos of the subjects' facial skin at week 0, week 2, and week 4 (texture parts are marked by software). Figure 7 shows the change in the relative amount of red spots on the skin of subjects after applying the extract of tartary buckwheat seed coat for four consecutive weeks. *p value>0.05. Figures 8 to 10 are images of the subjects' facial skin taken by the tester at week 0, week 2, and week 4 respectively.
Claims (8)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859754P | 2019-06-11 | 2019-06-11 | |
| US62/859,754 | 2019-06-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202045134A true TW202045134A (en) | 2020-12-16 |
| TWI801738B TWI801738B (en) | 2023-05-11 |
Family
ID=73656134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109119752A TWI801738B (en) | 2019-06-11 | 2020-06-11 | Use of seed coat extracts of fagopyrum tataricum for reducing the loss of elastin |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN115040564A (en) |
| TW (1) | TWI801738B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100711007B1 (en) * | 2005-07-28 | 2007-04-25 | 재단법인춘천바이오산업진흥원 | Functional Cosmetic Composition Comprising Extract of Fagopyrum esculentum |
| FR2918569B1 (en) * | 2007-07-09 | 2012-09-28 | Engelhard Lyon | SUBSTANCES INHIBITING GLYCATION OF PROTEINS. |
| CN102630790B (en) * | 2012-05-08 | 2015-02-11 | 四川九通慧医药信息科技有限公司 | Tartary buckwheat tea prepared by Ginkgo biloba leaf and preparation process thereof |
| CN105795480A (en) * | 2016-04-08 | 2016-07-27 | 吉林鑫水科技开发有限公司 | Extraction and analysis method and application of flavone in buckwheat |
| CN110710682A (en) * | 2018-07-12 | 2020-01-21 | 大江生医股份有限公司 | Application of tartary buckwheat seed coat extract in improving mitochondrial activity, promoting anti-aging gene expression and inhibiting protein glycosylation |
| CN109674711A (en) * | 2019-03-01 | 2019-04-26 | 安徽省钗源苦荞麦制品有限责任公司 | Tartary buckwheat facial mask liquid and preparation method thereof |
-
2020
- 2020-06-11 TW TW109119752A patent/TWI801738B/en active
- 2020-06-11 CN CN202210896717.3A patent/CN115040564A/en active Pending
- 2020-06-11 CN CN202010533517.2A patent/CN112057502A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115040564A (en) | 2022-09-13 |
| TWI801738B (en) | 2023-05-11 |
| CN112057502A (en) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI693899B (en) | Fermentation product of punica granatum and uses thereof | |
| CN111686039B (en) | Whitening and skin-brightening composition and preparation method thereof | |
| TW201225989A (en) | Sugar-free pineapple extract, production method thereof, and application thereof | |
| TW202106319A (en) | Use of protea plant extract for skin anti-aging | |
| KR20130043438A (en) | Composition for skin wrinkle improvement comprising extracts of junglans mandshurica maxim as an active ingredient | |
| KR101474998B1 (en) | Composition comprising extracts of white tea for the care of skin wrinkle | |
| TW202115241A (en) | Fermentation broth of actinidia deliciosa and uses thereof for beautifying skin | |
| TW202103682A (en) | Use of aronia melanocarpa juice for inhibiting skin aging | |
| TW202106330A (en) | Use of phalaenopsis plant extract for anti-glycation and improving skin appearance | |
| TWI801738B (en) | Use of seed coat extracts of fagopyrum tataricum for reducing the loss of elastin | |
| TWI809300B (en) | Use of ilex latifolia thunb extract | |
| TW202102250A (en) | Fermentation product of black rice extract and preparation and use of the same | |
| WO2024008187A1 (en) | Use of prunus lannesiana extract in preparation of drug for improving skin condition or basal metabolic rate | |
| KR102520908B1 (en) | Preparation of aged solution of fruit of dioscorea opposita thumb, and aged solution of fruit of dioscorea opposita thumb prepared thereby | |
| TW202011978A (en) | Integrated fruits and vegetables and berries ferment, preparation method thereof and use thereof | |
| TWI830382B (en) | Prunus salicina ferment, manufacturing method thereof, and uses thereof | |
| TWI820448B (en) | Use of rubus fruticosus extract for manufacturing a skincare composition | |
| CN112842956B (en) | Application of Cymbopogon citratus to conditioning skin | |
| TWI754137B (en) | Angelica dahurica ferment, preparation method thereof and use thereof for improving skin appearance | |
| TWI788019B (en) | Use of chamaemelum nobile extract for manufacturing skincare composition | |
| TWI834368B (en) | Uses of white bayberry extract for resisting aging or reducing fat | |
| TWI835432B (en) | USE OF LONGAN FLOWER EXTRACT FOR INHIBITION OF β-GALACTOSIDASE ACTIVITY OF STEM CELL AND PROMOTING SKIN HEALTH | |
| TWI804771B (en) | Uses of coffee cherry extract for inhibiting and/or reducing the production of collagen glycation end-products | |
| JP2004359554A (en) | Age resister and external preparation for skin | |
| CN115530303A (en) | Assayl and blood orange composition with whitening effect |